Raytelligence decides on an expansive rights issue

9 huhtikuuta 2020

Raytelligence offers products and services for non-contact monitoring vital signs of humans, that is respiration, heartbeat and motion patterns based on the company’s own 60 GHz radar technology.

The rights issue of maximum SEK 5.4 million is carried out to provide funds for additional marketing activities internationally.

Augment is acting as financial advisor to Raytelligence in connection with the transaction.

Read full press release (in Swedish)